A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MM

Status:
Not yet recruiting

Trial end date:
2024-12-31

Target enrollment:

Participant gender:

This is an open-label, single arm study to access the effect of treatment with D-VRD in patients with newly diagnosed standard risk multiple myeloma.

N/A

The First Affiliated Hospital of Soochow University

Daratumumab